Drug Report History #280445
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v2-FR | Version v1-EN |
|---|---|---|
| Language | French (Updated) | English |
| Date Updated | 2026-03-12 | 2026-03-12 |
| Drug Identification Number | 02240255 | 02240255 |
| Brand name | ADACEL | ADACEL |
| Common or Proper name | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed |
| Company Name | SANOFI VACCINES CANADA LTD. | SANOFI VACCINES CANADA LTD. |
| Ingredients | TETANUS TOXOID FIMBRIAE TYPES 2 AND 3 PERTACTIN FILAMENTOUS HAEMAGGLUTININ DIPHTHERIA TOXOID PERTUSSIS TOXOID | TETANUS TOXOID FIMBRIAE TYPES 2 AND 3 PERTACTIN FILAMENTOUS HAEMAGGLUTININ DIPHTHERIA TOXOID PERTUSSIS TOXOID |
| Strength(s) | 5LF 5MCG 3MCG 5MCG 2LF 2.5MCG | 5LF 5MCG 3MCG 5MCG 2LF 2.5MCG |
| Dosage form(s) | SUSPENSION | SUSPENSION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 10 x 0.5 mL vials | 10 x 0.5 mL vials |
| Anatomical Therapeutical Chemical (ATC) code | J07AJ | J07AJ |
| Anatomical Therapeutical Chemical (ATC) description | BACTERIAL VACCINES | BACTERIAL VACCINES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2026-03-10 | 2026-03-10 |
| Actual start date | 2026-03-10 | 2026-03-10 |
| Estimated end date | 2026-04-24 | 2026-04-24 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | A supplier has identified a defect potentially impacting batches of Adacel intended for release to the Canadian market. Sanofi is working to resolve the situation as soon as possible, and identify options to mitigate any potential impact. | A supplier has identified a defect potentially impacting batches of Adacel intended for release to the Canadian market. Sanofi is working to resolve the situation as soon as possible, and identify options to mitigate any potential impact. |
| Health Canada comments |